Literature DB >> 1378515

Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease.

H Jacobsen1, L Ahlborn-Laake, R Gugel, J Mous.   

Abstract

We have evaluated a possible role for human immunodeficiency virus type 1 protease during early steps of replication. For these studies, a specific inhibitor of human immunodeficiency virus protease, Ro31-8959, was used. Synthesis of viral cDNA, its integration into cellular DNA, and its transcription were determined during a one-step, acute infection of MT-4 cells. No consistent difference in any of these parameters was noted between control-infected cultures and those treated with protease inhibitor. However, no infectious progeny virus was produced in treated cultures, and thus spread of infection was severely restricted. Our results do not support an essential activity of viral protease in early steps of replication but are in line with its established role in gag and gag-pol processing and in maturation to infectious progeny virus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378515      PMCID: PMC241373     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

2.  Mutation of conserved N-glycosylation sites around the CD4-binding site of human immunodeficiency virus type 1 GP120 affects viral infectivity.

Authors:  L Dirckx; D Lindemann; R Ette; C Manzoni; D Moritz; J Mous
Journal:  Virus Res       Date:  1990-12       Impact factor: 3.303

3.  3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase.

Authors:  M H St Clair; C A Richards; T Spector; K J Weinhold; W H Miller; A J Langlois; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

4.  Characterization of ribosomal frameshifting in HIV-1 gag-pol expression.

Authors:  T Jacks; M D Power; F R Masiarz; P A Luciw; P J Barr; H E Varmus
Journal:  Nature       Date:  1988-01-21       Impact factor: 49.962

5.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

6.  Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.

Authors:  P S Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

7.  In situ processing of a retroviral nucleocapsid protein by the viral proteinase.

Authors:  M M Roberts; T D Copeland; S Oroszlan
Journal:  Protein Eng       Date:  1991-08

8.  HIV-1 proteinase is required for synthesis of pro-viral DNA.

Authors:  C Baboonian; A Dalgleish; L Bountiff; J Gross; S Oroszlan; G Rickett; C Smith-Burchnell; P Troke; J Merson
Journal:  Biochem Biophys Res Commun       Date:  1991-08-30       Impact factor: 3.575

9.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

10.  Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase.

Authors:  J C Craig; I B Duncan; D Hockley; C Grief; N A Roberts; J S Mills
Journal:  Antiviral Res       Date:  1991-12       Impact factor: 5.970

View more
  10 in total

1.  HIV-1 protease cleaves eukaryotic initiation factor 4G and inhibits cap-dependent translation.

Authors:  I Ventoso; R Blanco; C Perales; L Carrasco
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

2.  Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication.

Authors:  A H Kaplan; M Manchester; T Smith; Y L Yang; R Swanstrom
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

3.  Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture.

Authors:  M Nascimbeni; C Lamotte; G Peytavin; R Farinotti; F Clavel
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

4.  Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.

Authors:  A H Kaplan; J A Zack; M Knigge; D A Paul; D J Kempf; D W Norbeck; R Swanstrom
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

5.  DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein.

Authors:  M M Rayner; B C Cordova; R P Meade; P E Aldrich; P K Jadhav; Y Ru; P Y Lam
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

6.  Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase.

Authors:  T Fujihashi; H Hara; T Sakata; K Mori; H Higuchi; A Tanaka; H Kaji; A Kaji
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

7.  Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.

Authors:  K Nagy; M Young; C Baboonian; J Merson; P Whittle; S Oroszlan
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

Review 8.  Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection.

Authors:  S Noble; D Faulds
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

9.  Effect of internal cleavage site mutations in human immunodeficiency virus type 1 capsid protein on its structure and function.

Authors:  Ferenc Tóth; János Kádas; János András Mótyán; József Tőzsér
Journal:  FEBS Open Bio       Date:  2016-06-30       Impact factor: 2.693

10.  Specificity of the HIV-1 Protease on Substrates Representing the Cleavage Site in the Proximal Zinc-Finger of HIV-1 Nucleocapsid Protein.

Authors:  János András Mótyán; Márió Miczi; Stephen Oroszlan; József Tőzsér
Journal:  Viruses       Date:  2021-06-08       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.